The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![New Zealand New Zealand flag](https://www.greenhill.com/sites/default/files/new-zealand_flag_40105.gif)
Restaurant Brands New Zealand Limited
![](https://www.greenhill.com/sites/default/files/uk_india_flags2.png)
Advised Finaccess Capital, an investment company with a strong presence in the casual dining and quick service restaurant sector, on its 75% partial takeover of Restaurant Brands New Zealand, a corporate franchisee specialising in managing multi-site branded food retail chains (with brands consisting of KFC, Pizza Hut, Taco Bell and Carl’s Jr.)
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Montserrat Day Hospital Group
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
![](https://www.greenhill.com/sites/default/files/australia-indonesia-flag.png)
Martabe gold and silver mine
![](https://www.greenhill.com/sites/default/files/australia-indonesia-flag.png)
Advised EMR Capital, a specialist resources private equity manager, on the sale of the Martabe gold and silver mine to United Tractors
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Cura Imagem e Diagnóstico Ltda.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Cura Imagem e Diagnóstico Ltda.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advising Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Greenpark Aparcamientos
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Advised Oak Hill Advisors in the sale of Greenpark Aparcamientos, a leading off-street car park operator, to Parkia, a portfolio company of First State Investments
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
The Alpha Corporation (AOC Resins)
![Luxemboug Luxembourg flag](https://www.greenhill.com/sites/default/files/luxembourg.gif)
Advised AOC Resins, a leading global producer of polyester and vinyl ester resins, gel coats, colorants dispersions and specialty additives for composites and cast polymer applications, on its sale to CVC Capital Partners
![Spain, France flags](https://www.greenhill.com/sites/default/files/spain-france-flags.png)
IslaLink
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Grupo Sidecu
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Advised the shareholders of Grupo Sidecu, the leading concessional sport center operator in Spain, on its sale of a controlling stake to Portobello Capital, a local private equity fund
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
MorphoSys AG
![China China flag](https://www.greenhill.com/sites/default/files/china.gif)
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Jaybro
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Jaybro, a leading supplier of consumables to infrastructure contractors, on its sale to CHAMP Private Equity
![South Africa/Switzerland South Africa, Switzerland flags](https://www.greenhill.com/sites/default/files/s-africa_switz_91006.gif)
Hirslanden Private Hospital Group
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Thermamax
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised the shareholders of Thermamax, a leading family-owned manufacturer of highly engineered high temperature insulation solutions on the sale of the Company
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Radiogroup Participações S.A.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Rico
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised the founding shareholders of Rico, a leading independent online investment platform in Brazil, on its 100% sale to XP Investimentos, a Brazilian investment firm
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
![UK/Ireland U.K., Ireland flags](https://www.greenhill.com/sites/default/files/uk-ireland_35558.gif)
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Limited
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to an authorized generic version of Adderall XR
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 37 approved and 5 pipeline generic products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.